These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 9238061

  • 1. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease.
    Bilang-Bleuel A, Revah F, Colin P, Locquet I, Robert JJ, Mallet J, Horellou P.
    Proc Natl Acad Sci U S A; 1997 Aug 05; 94(16):8818-23. PubMed ID: 9238061
    [Abstract] [Full Text] [Related]

  • 2. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.
    Choi-Lundberg DL, Lin Q, Schallert T, Crippens D, Davidson BL, Chang YN, Chiang YL, Qian J, Bardwaj L, Bohn MC.
    Exp Neurol; 1998 Dec 05; 154(2):261-75. PubMed ID: 9878166
    [Abstract] [Full Text] [Related]

  • 3. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat.
    Connor B, Kozlowski DA, Schallert T, Tillerson JL, Davidson BL, Bohn MC.
    Gene Ther; 1999 Dec 05; 6(12):1936-51. PubMed ID: 10637445
    [Abstract] [Full Text] [Related]

  • 4. Adenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides neuroprotection in the aged parkinsonian rat.
    Connor B.
    Clin Exp Pharmacol Physiol; 2001 Nov 05; 28(11):896-900. PubMed ID: 11703392
    [Abstract] [Full Text] [Related]

  • 5. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease.
    Lapchak PA, Araujo DM, Hilt DC, Sheng J, Jiao S.
    Brain Res; 1997 Nov 28; 777(1-2):153-60. PubMed ID: 9449424
    [Abstract] [Full Text] [Related]

  • 6. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
    Connor B, Kozlowski DA, Unnerstall JR, Elsworth JD, Tillerson JL, Schallert T, Bohn MC.
    Exp Neurol; 2001 May 28; 169(1):83-95. PubMed ID: 11312561
    [Abstract] [Full Text] [Related]

  • 7. Protective effects of intracerebral adenoviral-mediated GDNF gene transfer in a rat model of Parkinson's disease.
    Chen X, Liu W, Guoyuan Y, Liu Z, Smith S, Calne DB, Chen S.
    Parkinsonism Relat Disord; 2003 Oct 28; 10(1):1-7. PubMed ID: 14499199
    [Abstract] [Full Text] [Related]

  • 8. Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease.
    Do Thi NA, Saillour P, Ferrero L, Dedieu JF, Mallet J, Paunio T.
    Gene Ther; 2004 May 28; 11(9):746-56. PubMed ID: 14724667
    [Abstract] [Full Text] [Related]

  • 9. Dopaminergic neurons protected from degeneration by GDNF gene therapy.
    Choi-Lundberg DL, Lin Q, Chang YN, Chiang YL, Hay CM, Mohajeri H, Davidson BL, Bohn MC.
    Science; 1997 Feb 07; 275(5301):838-41. PubMed ID: 9012352
    [Abstract] [Full Text] [Related]

  • 10. Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease.
    Yasuhara T, Shingo T, Muraoka K, Kobayashi K, Takeuchi A, Yano A, Wenji Y, Kameda M, Matsui T, Miyoshi Y, Date I.
    J Neurosurg; 2005 Jan 07; 102(1):80-9. PubMed ID: 15658100
    [Abstract] [Full Text] [Related]

  • 11. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.
    Rosenblad C, Kirik D, Devaux B, Moffat B, Phillips HS, Björklund A.
    Eur J Neurosci; 1999 May 07; 11(5):1554-66. PubMed ID: 10215908
    [Abstract] [Full Text] [Related]

  • 12. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
    Björklund A, Kirik D, Rosenblad C, Georgievska B, Lundberg C, Mandel RJ.
    Brain Res; 2000 Dec 15; 886(1-2):82-98. PubMed ID: 11119690
    [Abstract] [Full Text] [Related]

  • 13. Intranigral ventral mesencephalic grafts and nigrostriatal injections of glial cell line-derived neurotrophic factor restore dopamine release in the striatum of 6-hydroxydopamine-lesioned rats.
    Tang FI, Tien LT, Zhou FC, Hoffer BJ, Wang Y.
    Exp Brain Res; 1998 Apr 15; 119(3):287-96. PubMed ID: 9551829
    [Abstract] [Full Text] [Related]

  • 14. Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease.
    Voutilainen MH, Bäck S, Pörsti E, Toppinen L, Lindgren L, Lindholm P, Peränen J, Saarma M, Tuominen RK.
    J Neurosci; 2009 Jul 29; 29(30):9651-9. PubMed ID: 19641128
    [Abstract] [Full Text] [Related]

  • 15. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease.
    Cunningham LA, Su C.
    Exp Neurol; 2002 Apr 29; 174(2):230-42. PubMed ID: 11922664
    [Abstract] [Full Text] [Related]

  • 16. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector.
    Georgievska B, Kirik D, Rosenblad C, Lundberg C, Björklund A.
    Neuroreport; 2002 Jan 21; 13(1):75-82. PubMed ID: 11924898
    [Abstract] [Full Text] [Related]

  • 17. Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain.
    Kojima H, Abiru Y, Sakajiri K, Watabe K, Ohishi N, Takamori M, Hatanaka H, Yagi K.
    Biochem Biophys Res Commun; 1997 Sep 18; 238(2):569-73. PubMed ID: 9299553
    [Abstract] [Full Text] [Related]

  • 18. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages.
    Aoi M, Date I, Tomita S, Ohmoto T.
    Neurosci Res; 2000 Apr 18; 36(4):319-25. PubMed ID: 10771110
    [Abstract] [Full Text] [Related]

  • 19. Adeno-associated virus type 2 vector-mediated glial cell line-derived neurotrophic factor gene transfer induces neuroprotection and neuroregeneration in a ubiquitin-proteasome system impairment animal model of Parkinson's disease.
    Du Y, Zhang X, Tao Q, Chen S, Le W.
    Neurodegener Dis; 2013 Apr 18; 11(3):113-28. PubMed ID: 22626907
    [Abstract] [Full Text] [Related]

  • 20. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease.
    Mandel RJ, Snyder RO, Leff SE.
    Exp Neurol; 1999 Nov 18; 160(1):205-14. PubMed ID: 10630205
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.